Kyverna Therapeutics Files DEFA14A Proxy Materials
Ticker: KYTX · Form: DEFA14A · Filed: Apr 13, 2026
Sentiment: neutral
Topics: proxy-filing, shareholder-communication, sec-filing
Related Tickers: KYRN
TL;DR
KYRN filed proxy docs, check for shareholder votes.
AI Summary
Kyverna Therapeutics, Inc. filed a DEFA14A on April 13, 2026, related to additional definitive proxy soliciting materials. The filing, with SEC Accession Number 0001193125-26-152870, contains three documents including the main DEFA14A filing and two graphic files. The company's mailing and business address is 5980 Horton Street, Suite 550, Emeryville, CA 94608.
Why It Matters
This filing indicates important shareholder communications and potential upcoming decisions or votes for Kyverna Therapeutics, Inc. shareholders.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not inherently indicate significant new risks.
Key Numbers
- 0001193125-26-152870 — SEC Accession Number (Unique identifier for this specific filing)
- 2026-04-13 — Filing Date (Date the filing was accepted by the SEC)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Filer of the DEFA14A
- 0001193125-26-152870 (dollar_amount) — SEC Accession Number for the filing
- 2026-04-13 (dollar_amount) — Filing Date
- 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 (dollar_amount) — Company Mailing and Business Address
FAQ
What type of filing is this DEFA14A for Kyverna Therapeutics?
This DEFA14A filing is for additional definitive proxy soliciting materials and Rule 14(a)(12) material.
What is the SEC Accession Number for this filing?
The SEC Accession Number for this filing is 0001193125-26-152870.
When was this DEFA14A filing accepted by the SEC?
This filing was accepted on 2026-04-13.
What is Kyverna Therapeutics' business address?
Kyverna Therapeutics' business address is 5980 Horton Street, Suite 550, Emeryville, CA 94608.
What is the SIC code for Kyverna Therapeutics?
The SIC code for Kyverna Therapeutics is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 13, 2026 regarding Kyverna Therapeutics, Inc. (KYTX).